[1] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290):2212-2224. [2] 施漪雯,范建高.代谢相关性脂肪性肝病流行现状. 实用肝脏病杂志, 2023, 26(6):777-780. [3] Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7):1999-2014,e1. [4] 中华医学会肝病学分会,范建高,南月敏,等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志, 2024, 27(4):494-510. [5] Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology, 2017, 65(5):1557-1565. [6] Ng CH, Lim WH, Hui Lim GE, et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2023, 21(4):931-939,e5. [7] Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Curr Hepatol Rep, 2018, 17(4):350-360. [8] Venkatesan N, Doskey LC, Malhi H. The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. Am J Pathol, 2023, 193(12):1887-1899. [9] Xu HL, Wan SR, An Y, et al. Targeting cell death in NAFLD: mechanisms and targeted therapies. Cell Death Discov, 2024, 10(1):399. [10] Tareen K, Clifton EG, Perumalswami P, et al. Treatment of alcohol use disorder: behavioral and pharmacologic therapies. Clin Liver Dis, 2024, 28(4):761-778. [11] Zeng M, Wu B, Wei W, et al. Disulfiram: a novel repurposed drug for cancer therapy. Chin Med J (Engl), 2024, 137(12):1389-1398. [12] Liu T, Wang P, Cong M, et al. Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. Br J Pharmacol, 2018, 175(24):4480-4495. [13] Le TKC, Dao XD, Nguyen DV, et al. Insulin signaling and its application. Front Endocrinol (Lausanne), 2023, 14:1226655. [14] Wu J, Park SH, Choi E. The insulin receptor endocytosis. Prog Mol Biol Transl Sci, 2023, 194:79-107. [15] James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol, 2021, 22(11):751-771. [16] Saltiel AR. Insulin signaling in health and disease. J Clin Invest, 2021, 131(1):e142241. [17] Chen Y, Huang L, Qi X, et al. Insulin receptor trafficking: consequences for insulin sensitivity and diabetes. Int J Mol Sci, 2019, 20(20):5007. [18] Hall C, Yu H, Choi E. Insulin receptor endocytosis in the pathophysiology of insulin resistance. Exp Mol Med, 2020, 52(6):911-920. [19] Chen Y, Du X, Kuppa A, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet, 2023, 55(10):1640-1650. [20] Yang P, Liang Y, Luo Y, et al. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway. Diabetes Metab Syndr Obes, 2019, 12:1013-1021. [21] Zheng T, Jiang T, Ma H, et al. Targeting PI3K/Akt in cerebral ischemia reperfusion injury alleviation: from signaling networks to targeted therapy. Mol Neurobiol, 2024, 61(10):7930-7949. |